Guillain-Barré syndrome after treatment with sunitinib malate?
Oncology (Williston Park)
; 22(1): 66-7, 70-1, 2008 Jan.
Article
em En
| MEDLINE
| ID: mdl-18251284
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor used for treatment of renal cell carcinoma and gastrointestinal stromal tumor. We report a case of a patient who developed Guillain-Barrd syndrome after initial treatment with sunitinib, with recurrent symptoms upon reintroducing the drug. This is the first report of such an effect. The literature on chemotherapy-induced Guillain-Barri syndrome is also reviewed. Oncology providers should be aware of this rare but potentially serious possible adverse effect of sunitinib.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirróis
/
Síndrome de Guillain-Barré
/
Indóis
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Oncology (Williston Park)
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos